Levothyroxine overuse: time for an about face?

The Lancet Diabetes and Endocrinology

Volumn 5, Issue 4, 2017, Pages 246-248

  Rodriguez Gutierrez, Rene ^a,b   Maraka, Spyridoula ^a   Ospina, Naykky Singh ^a   Montori, Victor M ^a   Brito, Juan P ^a  

^a MAYO CLINIC   (United States)

^b HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOTHYROXINE; THYROTROPIN; THYROXINE;

CARDIOVASCULAR RISK; COGNITION; CONCENTRATION (PARAMETERS); DRUG MISUSE; DRUG SAFETY; HEALTH CARE COST; HEALTH CARE QUALITY; HORMONE SUBSTITUTION; HUMAN; HYPOTHYROIDISM; INCIDENCE; NOTE; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; QUALITY OF LIFE; RISK ASSESSMENT; SCREENING; UNITED KINGDOM; UNITED STATES; INAPPROPRIATE PRESCRIBING; MEDICATION OVERUSE; STATISTICS AND NUMERICAL DATA;

HUMANS; HYPOTHYROIDISM; INAPPROPRIATE PRESCRIBING; PRESCRIPTION DRUG OVERUSE; THYROXINE;

EID: 85006013044     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(16)30276-5     Document Type: Note

References (11)

1. 1 Brown, T, 100 best-selling, most prescribed branded drugs through March. http://www.medscape.com/viewarticle/844317, 2015 (accessed Aug 15, 2016).
2. 2 Prescribing and Primary Care Services, Health and Social Care Information Center. Prescriptions dispensed in the community: England 2004–14. http://content.digital.nhs.uk/catalogue/PUB11291/pres-disp-com-eng-2002-12-rep.pdf (accessed Aug 15, 2016).
3. 3 Villar, HC, Saconato, H, Valente, O, Atallah, AN, Thyroid hormone replacement for subclinical hypothyroidism. Cochrane Database Syst Rev, 3, 2007 CD003419.
4. 4 Rosario, PW, Calsolari, MR, How selective are the new guidelines for treatment of subclinical hypothyroidism for patients with thyrotropin levels at or below 10 mIU/L?. Thyroid 23 (2013), 562–565.
5. 5 Asvold, BO, Vatten, LJ, Bjoro, T, Changes in the prevalence of hypothyroidism: the HUNT Study in Norway. Eur J Endocrinol 169 (2013), 613–620.
6. 6 Taylor, PN, Iqbal, A, Minassian, C, et al. Falling threshold for treatment of borderline elevated thyrotropin levels-balancing benefits and risks: evidence from a large community-based study. JAMA Intern Med 174 (2014), 32–39.
7. 7 Meyerovitch, J, Rotman-Pikielny, P, Sherf, M, Battat, E, Levy, Y, Surks, MI, Serum thyrotropin measurements in the community: five-year follow-up in a large network of primary care physicians. Arch Intern Med 167 (2007), 1533–1538.
8. 8 Canaris, GJ, Manowitz, NR, Mayor, G, Ridgway, EC, The Colorado thyroid disease prevalence study. Arch Intern Med 160 (2000), 526–534.
9. 9 Maraka, S, Singh Ospina, NM, O'Keeffe, DT, et al. Effects of levothyroxine therapy on pregnancy outcomes in women with subclinical hypothyroidism. Thyroid 26 (2016), 980–986.
10. 10 Somwaru, LL, Arnold, AM, Joshi, N, Fried, LP, Cappola, AR, High frequency of and factors associated with thyroid hormone over-replacement and under-replacement in men and women aged 65 and over. J Clin Endocrinol Metab 94 (2009), 1342–1345.
11. 11 Rodriguez-Gutierrez, R, Gionfriddo, MR, Ospina, NS, et al. Shared decision making in endocrinology: present and future directions. Lancet Diabetes Endocrinol 4 (2016), 706–716.